For further information or prices please contact us:
Detox & Cleanse Ingredient Intelligence: Mechanisms, Standardization & Regulatory Status
A scientific guide to ingredient selection for detox and cleanse formulations, covering mechanistic rationale, standardization, analytical markers, safety considerations, regulatory status, formulation compatibility, and market-specific suitability.
Ingredient Portfolio — Sourcing, Characterisation & Regulatory Status
Every ingredient entering FRL formulation is evaluated against four criteria: scientific rationale, standardization and analytically controllable profile, toxicity, and market authorization. An ingredient failing on the last criterion is eliminated at early-stage concept development rather than dossier stage.
| Ingredient | Mechanistic rationale | Standardisation / analytical marker | Regulatory watch-points |
| Milk thistle (Silybum marianum) | Membrane stabilisation; supports glutathione status; antioxidant | Silymarin flavonolignan sum by HPLC-DAD; silybin A/B ratio; phosphatidylcholine complex ratio | Pre-cleared via Health Canada NNHPD monograph; a notified functional ingredient for liver health under Korea MFDS. No usable EU claim — see Novel Nutriology below. |
| Artichoke (Cynara scolymus) | Choleretic; supports bile secretion and lipid digestion | Chlorogenic acid and cynarin by HPLC; cynaropicrin for bitterness control | NNHPD monograph exists. Bitter sesquiterpene lactones require taste-masking in beverage formats. |
| Dandelion (Taraxacum officinale) | Choleretic and diuretic tradition of use | Taraxasterol; inulin content; root versus leaf distinction is material | Traditional-use claims available in monograph markets. Asteraceae cross-reactivity requires allergen labelling assessment. |
| Turmeric (Curcuma longa) | Nrf2 activation; NF-κB modulation | Total curcuminoids ≥ 95% by HPLC; curcumin : demethoxycurcumin : bisdemethoxycurcumin profile | Idiosyncratic hepatotoxicity signal for high-bioavailability forms — see restricted-ingredient section. |
| Schisandra (Schisandra chinensis) | Lignan-mediated cytoprotection; adaptogenic tradition | Schisandrin and γ-schisandrin by HPLC | Novel food status must be confirmed for the EU; species and plant part must be specified precisely. |
| Broccoli sprout / glucoraphanin | Sulforaphane precursor; potent Nrf2–ARE inducer | Glucoraphanin by HPLC; myrosinase activity or stabilised sulforaphane yield | Yield depends on myrosinase co-formulation or gut microbial conversion — specify sulforaphane yield, not glucoraphanin alone. |
| Ashwagandha (Withania somnifera) | Adaptogenic; common in detox and stress-adjacent blends | Withanolide glycosides by HPLC; root versus leaf material must be declared | Under active EU scrutiny. Facing possible Article 8 restriction under Reg (EC) 1925/2006 on hepatic safety grounds; already restricted in some member states. Treat as an at-risk ingredient for EU-bound formulations. |
| Ingredient | Mechanistic rationale | Standardisation / analytical marker | Regulatory watch-points |
| N-acetyl-L-cysteine | Cysteine donor for glutathione synthesis | Assay by HPLC; residual solvent and heavy-metal control | Excluded from the US dietary supplement definition; on market under FDA enforcement discretion per the August 2022 final guidance, with rulemaking signalled but not published. Regulated as a medicinal product in several EU member states. |
| Alpha-lipoic acid | Redox-cycling cofactor; regenerates other antioxidants | R- versus racemic form; assay by HPLC | Enantiomer form affects permitted dose treatment in some markets. Insulin-autoimmune-syndrome signal in specific East Asian HLA genotypes. |
| Vitamins C and E, selenium, zinc, copper, manganese, riboflavin | Cofactors and direct antioxidants; substrate for glutathione peroxidase | Assay by HPLC / ICP-MS; overage justified by stability data | Each carries an authorised EU claim for contributing to the protection of cells from oxidative stress. This is the only reliable route to a compliant EU antioxidant claim. Tolerable upper intake levels and member-state maxima apply. |
| Resveratrol | Sirtuin and Nrf2 signalling | trans-Resveratrol by HPLC; isomer control | Synthetic trans-resveratrol is authorised as an EU novel food for adult food supplements with dose and labelling conditions. Botanical-source status differs and must be established separately. |
| Quercetin | Flavonol antioxidant; enzyme modulation | Aglycone versus glycoside quantitation by HPLC | UGT and SULT inhibition potential — relevant to herb–drug interaction assessment and to Phase II coupling. |
- Viscous soluble fibres — psyllium husk, partially hydrolysed guar gum, glucomannan, beta-glucan. Measured as total dietary fibre using AOAC 991.43 / 2009.01 / 2011.25. Claim-carrying amounts are large and format-defining; see claim mapping table.
- Prebiotic oligosaccharides — chicory root inulin, FOS, GOS, resistant dextrin. Degrees of polymerisation and purity are critical for both tolerance and efficacy. Osmotic load must be predicted with respect to serving size to ensure no dose-dependent bloating at the claim-required amount.
- Probiotic strains — identified via whole-genome sequencing, not just 16S; antimicrobial resistance gene screens; EFSA QPS status where EU marketing; enumeration by plate count and flow cytometry to ISO 19344 when appropriate. Viability established throughout shelf-life to claim amount, not manufacture. Noted that probiotic per se is a health claim and permitted in some member states and not others – label copy needs to reflect market-specific regulations.
- Digestive enzymes — activity units by validated assay, not mass. Activity is the specification.
Key Contact
Let’s create something Innovative and Delicious together
Food Research Lab strives for excellence in new Food, Beverage and Nutraceutical Product Research and Development by offering cutting edge scientific analysis and expertise.
